Drugs / CTS2190
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06224387 | Jun 2023 → Jul 2025 overdue | malignant pancreatic neoplasm, non-small cell lung carcinoma, triple-negative breast carcinoma | CytosinLab Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTS2190 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06224387 ↗ |
| Action | Inhibit | “PRMT1 inhibitor” NCT06224387 ↗ |
| Route | Oral | “administered orally” NCT06224387 ↗ |
| Target | PRMT1 | “PRMT1 inhibitor” NCT06224387 ↗ |